Y-3 for injection

DRUG2 trials

Sponsors

Beijing Tiantan Hospital, Neurodawn Pharmaceutical Co., Ltd.

Conditions

Acute Ischemic StrokePharmacokinetic Study in Healthy VolunteersSafetyTolerability

Phase 1

A Phase 1 Study of Y-3 in US Healthy Volunteers.

CompletedNCT06770491

Neurodawn Pharmaceutical Co., Ltd.Pharmacokinetic Study in Healthy Volunteers, Safety, Tolerability

Start: 2025-02-04End: 2025-09-20Updated: 2025-12-18

Phase 3

Y-3 for Injection in the Treatment of Acute Ischemic Stroke

RecruitingNCT06517173

Beijing Tiantan HospitalAcute Ischemic Stroke

Start: 2024-07-24End: 2025-07-31Target: 998Updated: 2024-09-19

Related Papers

Loberamisal for Acute Ischaemic Stroke (LAIS): a multicentre, randomised, double-blind, parallel, placebo-controlled phase III clinical trial.

2025-12-04